Azacitidine STADA: Uses, Dosage & Side Effects
A hypomethylating agent (pyrimidine nucleoside analogue) for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia, and acute myeloid leukaemia in adults not eligible for stem cell transplantation
Azacitidine STADA Arzneimittel AG is a prescription medicine containing the active substance azacitidine, a hypomethylating agent belonging to the class of pyrimidine nucleoside analogues. It is used to treat adult patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML), and acute myeloid leukaemia (AML) who are not eligible for haematopoietic stem cell transplantation. Azacitidine works through a dual mechanism: it directly kills abnormal blood cells and restores the function of genes that control normal cell growth and differentiation. This medication is administered as a subcutaneous injection by a healthcare professional in a hospital or clinic setting. Clinical trials have demonstrated that azacitidine can improve blood counts, reduce the need for transfusions, delay progression to acute leukaemia, and improve overall survival in eligible patients.
Quick Facts: Azacitidine STADA
Key Takeaways
- Azacitidine STADA is a hypomethylating agent used to treat myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML), and acute myeloid leukaemia (AML) in adults who cannot receive a stem cell transplant.
- The standard treatment regimen involves subcutaneous injections of 75 mg/m² daily for 7 consecutive days every 28 days, with treatment continuing for at least 6 cycles to allow time for clinical response.
- The most common side effects are blood count abnormalities (anaemia, neutropenia, thrombocytopenia), injection site reactions, nausea, vomiting, and fatigue, which are typically most pronounced during the first two treatment cycles.
- Regular blood count monitoring is essential throughout treatment, as azacitidine causes significant myelosuppression that may require dose delays, dose reductions, or supportive care such as blood transfusions and growth factors.
- Azacitidine must not be used during pregnancy or breastfeeding due to its teratogenic potential; both women and men of reproductive potential must use effective contraception during and after treatment.
What Is Azacitidine STADA and What Is It Used For?
Azacitidine STADA Arzneimittel AG contains the active substance azacitidine, which is a pyrimidine nucleoside analogue of cytidine. It belongs to a class of anticancer medications known as hypomethylating agents (HMAs). These drugs work by reversing abnormal DNA methylation patterns that silence tumour suppressor genes in cancer cells. By restoring the expression of these genes, azacitidine helps the bone marrow produce normal, healthy blood cells instead of abnormal, cancerous ones.
The mechanism of action of azacitidine is dual in nature. At lower doses, azacitidine exerts its primary effect through inhibition of DNA methyltransferases (DNMTs), particularly DNMT1. When azacitidine is incorporated into DNA during cell replication, it forms irreversible covalent bonds with DNMT1, leading to proteasomal degradation of the enzyme. This results in global DNA hypomethylation and the re-expression of previously silenced genes, including those involved in cell differentiation, apoptosis (programmed cell death), and tumour suppression. At higher doses, azacitidine also exerts direct cytotoxic effects by incorporating into both DNA and RNA, disrupting nucleic acid metabolism and triggering cell death in rapidly dividing cells. Approximately 80–90% of azacitidine is incorporated into RNA and 10–20% into DNA.
Myelodysplastic syndromes (MDS) are a group of blood disorders in which the bone marrow fails to produce enough healthy blood cells. In MDS, the haematopoietic stem cells (the cells that give rise to all blood cells) become abnormal and produce defective blood cells that do not function properly and often die prematurely. This leads to low blood counts: anaemia (low red blood cells causing fatigue and breathlessness), neutropenia (low white blood cells increasing infection risk), and thrombocytopenia (low platelets increasing bleeding risk). MDS can progress to acute myeloid leukaemia (AML) in approximately 30% of patients, making effective treatment essential.
Azacitidine STADA is specifically approved by the European Medicines Agency (EMA) for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation with the following conditions:
- Intermediate-2 and high-risk myelodysplastic syndromes (MDS): According to the International Prognostic Scoring System (IPSS), these patients have a significant risk of progression to acute leukaemia and shortened survival. Azacitidine has been shown to improve overall survival, delay leukaemic transformation, and improve blood counts in these patients.
- Chronic myelomonocytic leukaemia (CMML): This is a myelodysplastic/myeloproliferative overlap syndrome characterised by persistent monocytosis (elevated monocytes in the blood) together with dysplasia of one or more myeloid cell lineages. Azacitidine is approved for CMML patients with 10–29% bone marrow blasts without myeloproliferative disorder.
- Acute myeloid leukaemia (AML): Azacitidine is approved for AML with 20–30% blasts and multi-lineage dysplasia, according to the WHO classification. This subtype of AML often arises from pre-existing MDS and is associated with particularly poor prognosis with conventional chemotherapy.
The landmark AZA-001 clinical trial (Fenaux et al., Lancet Oncology, 2009) demonstrated that azacitidine significantly improved overall survival compared to conventional care regimens in higher-risk MDS patients. The median overall survival was 24.5 months with azacitidine versus 15 months with conventional care, representing a clinically meaningful improvement. This trial established azacitidine as a standard of care for higher-risk MDS patients who are not transplant candidates.
Azacitidine STADA Arzneimittel AG is a generic version of azacitidine. It contains the same active substance at the same strength and in the same pharmaceutical form as the originator product. It has been approved based on demonstrated bioequivalence and meets identical quality, safety, and efficacy standards required by European regulatory authorities. The choice between different azacitidine brands may depend on hospital formulary decisions, availability, and cost considerations.
What Should You Know Before Receiving Azacitidine STADA?
Contraindications
There are specific situations in which azacitidine must not be used. Understanding these absolute contraindications is essential before treatment begins, and your haematologist will carefully review your medical history to ensure this medication is appropriate for you.
- Hypersensitivity: Do not receive azacitidine if you are allergic to the active substance azacitidine or to any of the excipients in the formulation (mannitol). Allergic reactions can range from mild skin reactions to severe anaphylaxis.
- Advanced malignant hepatic tumours: Azacitidine is contraindicated in patients with advanced malignant liver tumours. The drug undergoes partial hepatic metabolism, and impaired liver function from malignant infiltration may lead to increased toxicity and unpredictable drug exposure.
- Breastfeeding: Women must discontinue breastfeeding before starting azacitidine treatment. Azacitidine and its metabolites may pass into breast milk and could cause serious harm to the nursing infant.
Warnings and Precautions
Azacitidine causes significant myelosuppression (bone marrow suppression), leading to anaemia, neutropenia, and thrombocytopenia. These effects are most pronounced during the first two treatment cycles. Regular complete blood count monitoring is mandatory before each treatment cycle and as clinically indicated. You may require blood transfusions, growth factor support, or dose adjustments to manage these effects safely.
Before and during treatment with azacitidine, inform your doctor if any of the following apply to you:
- Liver disease: If you have a history of liver problems or abnormal liver function tests, your doctor will monitor liver function closely during treatment. Azacitidine can cause hepatotoxicity, including elevated liver enzymes, hepatic failure, and hepatic coma. Cases of hepatotoxicity have been reported in patients with pre-existing liver disease and in those receiving concomitant hepatotoxic medications. Patients with extensive tumour burden due to metastatic disease are at particular risk.
- Kidney disease: If you have impaired kidney function, your doctor may need to monitor renal function more closely. Renal abnormalities ranging from elevated serum creatinine to renal failure and death have been reported in patients receiving azacitidine, particularly when given intravenously in combination with other medications. Patients with pre-existing renal impairment should be monitored closely for kidney toxicity.
- Heart disease: If you have a history of heart problems, including congestive heart failure, recent myocardial infarction, or unstable angina, inform your doctor. While cardiac toxicity is not a primary concern with azacitidine, the significant fluid shifts and electrolyte changes associated with myelosuppression and their management could affect cardiac function.
- Tumour lysis syndrome (TLS): Patients with a large tumour burden prior to treatment may be at risk of tumour lysis syndrome, a potentially life-threatening condition caused by the rapid breakdown of cancer cells. This releases large amounts of intracellular contents into the bloodstream, leading to hyperuricaemia, hyperkalaemia, hyperphosphataemia, and hypocalcaemia. Your doctor may implement preventive measures such as hydration and allopurinol.
- Infections: Azacitidine-induced neutropenia significantly increases the risk of infections. Febrile neutropenia (fever with low white blood cells) is a common complication. Report any signs of infection immediately, including fever, chills, sore throat, cough, or painful urination. Your doctor may prescribe prophylactic antibiotics or antifungals during periods of severe neutropenia.
- Bleeding: Thrombocytopenia (low platelet count) caused by azacitidine increases the risk of bleeding. Report any unusual bruising, prolonged bleeding from cuts, nosebleeds, blood in urine or stools, or petechiae (small red spots on the skin). Platelet transfusions may be necessary during periods of severe thrombocytopenia.
- Necrotising fasciitis: Rare cases of necrotising fasciitis, including fatal cases, have been reported in patients receiving azacitidine, particularly at injection sites. If you develop tender, warm, or red skin, particularly with swelling or fever, seek immediate medical attention.
Your doctor will perform regular blood tests and clinical assessments to monitor for these potential complications throughout your treatment. Complete blood counts should be performed before each treatment cycle and as clinically indicated to monitor for haematological toxicity.
Pregnancy and Breastfeeding
Azacitidine must not be used during pregnancy. Preclinical studies in animals have shown that azacitidine is teratogenic (causes birth defects) and embryotoxic (harmful to the developing embryo and fetus). The drug crosses the placental barrier and can cause serious harm to the unborn child. If you are a woman of childbearing potential, you must use effective contraception during treatment and for 6 months after the last dose of azacitidine. If you become pregnant during treatment, you must inform your doctor immediately so that the risks and benefits of continuing treatment can be carefully evaluated.
Men receiving azacitidine treatment should use effective contraception during treatment and for 3 months after the last dose, as the drug may affect sperm and potentially cause harm to the developing embryo. Men should also consider sperm cryopreservation (freezing) before starting treatment, as azacitidine may impair male fertility.
Breastfeeding must be discontinued before starting treatment with azacitidine. It is not known whether azacitidine or its metabolites are excreted in human breast milk, but given the drug’s mechanism of action and potential for serious adverse reactions in nursing infants, breastfeeding is contraindicated during treatment.
Driving and Operating Machinery
Azacitidine may have a moderate influence on the ability to drive and use machines. Fatigue is a very common side effect of treatment. If you feel tired, dizzy, or unwell, you should not drive or operate machinery until these symptoms have resolved. Discuss any concerns about your ability to perform these activities safely with your doctor.
How Does Azacitidine Interact with Other Drugs?
Unlike many anticancer agents, azacitidine is not primarily metabolised by the cytochrome P450 enzyme system. It undergoes spontaneous hydrolysis in aqueous solution and is also deaminated by the enzyme cytidine deaminase, which is present in the liver and other tissues. As a result, clinically significant pharmacokinetic interactions with drugs metabolised by cytochrome P450 enzymes are considered unlikely. However, several important pharmacodynamic interactions should be considered, and you should always inform your doctor about all medications you are taking.
Major Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Other myelosuppressive agents (e.g., chemotherapy drugs) | Additive bone marrow suppression, increased risk of severe cytopenias | Close monitoring of blood counts required; dose adjustments may be necessary |
| Live vaccines (e.g., MMR, varicella, BCG, yellow fever) | Risk of vaccine-strain infection due to immunosuppression | Avoid during treatment and for several months after; use inactivated vaccines instead |
| Hepatotoxic agents (e.g., paracetamol in high doses, methotrexate, statins) | Increased risk of liver damage when combined with azacitidine | Monitor liver function closely; consider alternative medications where possible |
| Nephrotoxic agents (e.g., aminoglycosides, NSAIDs, contrast media) | Increased risk of renal toxicity | Monitor renal function; avoid combination when possible, especially during active treatment days |
Minor Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Anticoagulants (e.g., warfarin, heparin) | Increased bleeding risk when combined with azacitidine-induced thrombocytopenia | Monitor coagulation parameters and platelet counts closely; adjust anticoagulant dosing as needed |
| Anti-emetics (e.g., ondansetron, granisetron) | No negative interaction; commonly used as supportive care | Routinely co-administered to manage nausea and vomiting |
| Growth factors (e.g., G-CSF/filgrastim, erythropoietin) | No negative interaction; used as supportive care for cytopenias | Commonly co-administered; timing should be coordinated with treatment cycles |
| Cytidine deaminase inhibitors (e.g., tetrahydrouridine) | May increase azacitidine plasma levels by inhibiting its metabolic breakdown | Theoretical interaction; not commonly encountered in clinical practice |
It is important to note that while formal drug interaction studies with azacitidine have been limited, the potential for pharmacodynamic interactions (additive toxicity effects) remains clinically significant. Your haematologist will carefully review all your medications before and during treatment to minimise the risk of adverse interactions. Always inform your healthcare team about any new medications, including over-the-counter drugs and herbal supplements, that you start taking during azacitidine treatment.
What Is the Correct Dosage of Azacitidine STADA?
Azacitidine treatment must be initiated and monitored by a physician experienced in the use of chemotherapy agents. Pre-medication with anti-emetics (medicines to prevent nausea and vomiting) should be given before each dose, as gastrointestinal side effects are common, particularly during the first treatment cycles.
Adults
Standard Treatment Regimen
Dose: 75 mg/m² body surface area, subcutaneous injection
Schedule: Once daily for 7 consecutive days, followed by a 21-day rest period (28-day treatment cycle)
Duration: A minimum of 6 cycles is recommended. Treatment should continue for as long as the patient continues to benefit or until unacceptable toxicity occurs.
Note: Clinical responses may be delayed. Patients should be assessed for response after at least 6 cycles. Some patients may not show clinical improvement until after the 3rd or 4th cycle. Do not discontinue treatment prematurely based on early lack of response.
Alternative 5-Day Regimen
Dose: 75 mg/m² body surface area, subcutaneous injection
Schedule: Once daily for 5 consecutive days, followed by 2 days off, then 2 additional days of treatment (5-2-2 schedule within the 28-day cycle)
Note: This alternative schedule may be used when the standard 7-day regimen is not practical due to logistical or scheduling considerations.
Dose Adjustments for Toxicity
Dose modifications may be necessary based on haematological laboratory values and renal toxicity. Your doctor will monitor your blood counts before each treatment cycle and adjust the dose according to specific guidelines:
| Parameter | Nadir Value | Action |
|---|---|---|
| WBC or Platelet | Nadir ≥50% of baseline | Give 100% of dose in next cycle |
| WBC or Platelet | Nadir <50% of baseline and nadir >25% of baseline | Give 67% of dose in next cycle |
| WBC or Platelet | Nadir ≤25% of baseline | Give 50% of dose in next cycle |
If blood counts have not recovered by Day 28 (i.e., the next cycle is due), treatment should be delayed until recovery is adequate. If recovery takes more than 14 additional days, the patient should be re-assessed and the dose may need to be reduced as per the table above.
Renal Impairment
No specific dose adjustment is recommended for patients with renal impairment, as azacitidine is not primarily eliminated by the kidneys. However, patients should be monitored carefully for renal toxicity. If unexplained elevations in serum creatinine or blood urea nitrogen (BUN) occur, the next treatment cycle should be delayed until values return to normal or baseline, and the dose should be reduced by 50% for the subsequent cycle.
Hepatic Impairment
No specific dose adjustment is recommended for patients with mild to moderate hepatic impairment. However, azacitidine is contraindicated in patients with advanced malignant hepatic tumours. Liver function should be monitored prior to and during treatment, and azacitidine should be used with caution in patients with pre-existing liver disease.
Children
The safety and efficacy of azacitidine in children and adolescents below 18 years of age have not been established. There are no data available, and azacitidine should not be used in the paediatric population outside of clinical trials.
Elderly Patients
No specific dose adjustment is recommended for elderly patients. However, since renal function may be decreased in older individuals, it may be advisable to monitor renal function more closely. The median age of patients in pivotal clinical trials was approximately 69 years, and the drug has been studied extensively in this population.
Missed Dose
If you miss a scheduled injection, contact your healthcare team as soon as possible to arrange the next injection. Your doctor will advise you on how to adjust the treatment schedule. Do not attempt to make up for a missed dose by receiving additional injections.
Overdose
There is limited experience with overdose of azacitidine. In the event of an overdose, the patient should be monitored with appropriate blood counts and supportive treatment should be given as necessary. There is no specific antidote for azacitidine overdose. The primary concern with overdose would be exaggerated myelosuppression (severe cytopenias), and supportive care including blood product transfusions, growth factors, and infection prophylaxis would be the mainstay of management.
Azacitidine is always prepared and administered by trained healthcare professionals in a hospital or specialised clinic setting. The powder must be reconstituted with water for injection shortly before use. You will not self-administer this medication at home. Each injection is carefully calculated based on your body surface area.
What Are the Side Effects of Azacitidine STADA?
Like all medicines, azacitidine can cause side effects, although not everyone gets them. The most commonly reported adverse reactions with azacitidine include haematological reactions (anaemia, thrombocytopenia, neutropenia), gastrointestinal disorders (nausea, vomiting, diarrhoea, constipation), and injection site reactions. Your medical team will monitor you closely and provide supportive care to manage side effects.
It is important to understand that many of the blood count abnormalities seen with azacitidine reflect the drug’s intended action on the bone marrow. As azacitidine kills abnormal cells and the bone marrow begins to produce healthier cells, temporary worsening of blood counts (known as the “nadir”) is expected. Blood counts typically recover between treatment cycles, and many patients experience improving blood counts over the course of several treatment cycles as their bone marrow function improves.
Very Common
May affect more than 1 in 10 people
- Anaemia (low red blood cells), including need for transfusions
- Thrombocytopenia (low platelets), potentially causing bleeding
- Neutropenia (low white blood cells), increasing infection risk
- Febrile neutropenia (fever with low white blood cells)
- Pneumonia and other respiratory tract infections
- Nausea and vomiting
- Diarrhoea
- Constipation
- Injection site reactions (redness, pain, bruising, induration, itching)
- Fatigue and weakness (asthenia)
- Fever (pyrexia)
- Decreased appetite (anorexia)
- Joint pain (arthralgia)
- Bruising (ecchymosis) and petechiae
- Dizziness and headache
- Shortness of breath (dyspnoea)
Common
May affect up to 1 in 10 people
- Sepsis and septic shock (serious bloodstream infection)
- Urinary tract infections
- Cellulitis and skin infections
- Nasopharyngitis (common cold)
- Herpes simplex virus infections
- Abdominal pain
- Stomatitis (mouth inflammation and ulcers)
- Skin rash, pruritus (itching), and erythema (redness)
- Insomnia and anxiety
- Muscle pain (myalgia) and back pain
- Weight loss
- Elevated liver enzymes (ALT, AST)
- Elevated serum creatinine
- Hypokalaemia (low potassium levels)
- Peripheral oedema (swelling in legs or feet)
- Chest pain and malaise
- Epistaxis (nosebleeds)
Uncommon
May affect up to 1 in 100 people
- Tumour lysis syndrome (rapid cancer cell breakdown causing organ damage)
- Necrotising fasciitis (severe soft tissue infection), including at injection sites
- Hepatic failure and hepatic coma
- Renal tubular acidosis
- Interstitial lung disease and pulmonary fibrosis
- Sweet syndrome (acute febrile neutrophilic dermatosis)
- Pyoderma gangrenosum (painful skin ulceration)
Rare
May affect up to 1 in 1,000 people
- Differentiation syndrome (fever, respiratory distress, weight gain, multi-organ dysfunction)
- Severe allergic reactions including anaphylaxis
- Skin vasculitis (inflammation of blood vessels in the skin)
When to Seek Immediate Medical Attention
Contact your doctor or seek emergency medical care immediately if you experience any of the following during or after treatment with azacitidine:
- Signs of infection: Fever above 38°C, chills, sore throat, persistent cough, painful urination, or general feeling of being unwell – especially if your white blood cell count is low
- Signs of bleeding: Unusual or prolonged bleeding, blood in urine or stools, severe bruising, vomiting blood, or coughing up blood
- Signs of liver problems: Yellowing of the skin or eyes (jaundice), dark urine, persistent nausea or vomiting, abdominal pain in the upper right area
- Signs of kidney problems: Decreased urine output, swelling in feet or ankles, persistent nausea, confusion
- Injection site complications: Increasing redness, swelling, warmth, tenderness, or drainage at the injection site, which may indicate cellulitis or necrotising fasciitis
- Allergic reactions: Difficulty breathing, swelling of the face, lips, tongue, or throat, severe rash or hives
Many patients find that side effects, particularly nausea, injection site reactions, and cytopenias, are most severe during the first one to two treatment cycles and gradually improve with subsequent cycles as the bone marrow begins to respond to treatment. Your medical team will provide supportive care to help manage side effects and ensure your comfort throughout treatment.
How Should You Store Azacitidine STADA?
Proper storage of azacitidine is critical to maintaining the quality, safety, and effectiveness of the medication. As azacitidine is administered in a hospital or clinic setting, storage is generally managed by the pharmacy and nursing staff. However, understanding storage requirements can be helpful for patients who wish to be informed about their treatment.
The unreconstituted powder vials should be stored at temperatures not exceeding 25°C and kept in the original packaging to protect from light. Do not freeze the unreconstituted product. Keep the medication out of the reach and sight of children.
After reconstitution with water for injection, the resulting suspension may be stored in the vial or drawn into a syringe. If the reconstituted suspension is not used immediately, it can be refrigerated at 2–8°C for up to 8 hours. Before administration, the refrigerated suspension should be allowed to equilibrate to room temperature for approximately 30 minutes. If the reconstituted product is kept at room temperature (25°C), it must be administered within 45 minutes.
Do not use azacitidine after the expiry date printed on the vial label and outer carton. The expiry date refers to the last day of that month. Do not use any reconstituted suspension that appears discoloured, contains particulate matter, or shows any visible signs of deterioration. Any unused product or waste material should be disposed of in accordance with local requirements for cytotoxic waste.
What Does Azacitidine STADA Contain?
Azacitidine STADA Arzneimittel AG is presented as a white lyophilised (freeze-dried) powder for suspension for injection. Understanding the composition of the medication is important for identifying potential allergens and for healthcare professionals who prepare and administer the drug.
Active Substance
The active substance is azacitidine. Each vial contains 100 mg of azacitidine. After reconstitution with 4 ml of water for injection, each ml of suspension contains 25 mg of azacitidine. Azacitidine (chemical name: 4-amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one) is a pyrimidine nucleoside analogue of cytidine with a molecular formula of C8H12N4O5 and a molecular weight of 244.20 g/mol.
Excipient (Inactive Ingredient)
The only excipient in Azacitidine STADA is mannitol (E421). Mannitol serves as a bulking agent and lyoprotectant in the freeze-dried formulation, helping to maintain the structural integrity of the powder cake and facilitate reconstitution. Mannitol is a sugar alcohol that is generally well tolerated but should be noted by patients with rare hereditary fructose intolerance, as it may cause discomfort in these individuals.
Appearance
The unreconstituted product is a white to off-white lyophilised powder or cake. After reconstitution with water for injection, the resulting suspension should be a uniform, cloudy suspension free from agglomerates (large undissolved particles). The suspension should be gently inverted 2–3 times and rolled between the palms for 30 seconds immediately before administration to ensure uniformity. Do not filter the suspension after reconstitution, as this may remove the active substance.
Frequently Asked Questions About Azacitidine STADA
Azacitidine and decitabine are both hypomethylating agents (HMAs) used to treat myelodysplastic syndromes (MDS) and related conditions, but they differ in their chemistry and mechanism. Azacitidine is a ribonucleoside analogue that incorporates into both RNA (80–90%) and DNA (10–20%), while decitabine is a deoxyribonucleoside analogue that incorporates exclusively into DNA. Both drugs inhibit DNA methyltransferases, but azacitidine’s additional RNA effects may contribute to its distinct clinical profile. Azacitidine is the only HMA with a demonstrated overall survival benefit in a phase III clinical trial for higher-risk MDS (AZA-001). The choice between these agents often depends on clinical factors, treatment schedules, and local availability.
Azacitidine typically requires several treatment cycles before clinical benefit becomes apparent. Most patients begin to show improvement in blood counts after 3 to 6 cycles of treatment, though some may respond sooner. The median time to first response in clinical trials was approximately 2 cycles, but complete responses often take longer. It is crucial not to discontinue treatment prematurely, as a minimum of 6 cycles is recommended before concluding that the medication is not effective. Some patients who initially appear not to respond may achieve meaningful clinical benefit with continued treatment.
Azacitidine is not considered a curative treatment for MDS. The only potentially curative option for MDS is allogeneic haematopoietic stem cell transplantation, which is not suitable for all patients, particularly older adults or those with significant comorbidities. However, azacitidine can significantly improve quality of life by improving blood counts, reducing transfusion requirements, delaying progression to acute myeloid leukaemia, and extending overall survival. In the landmark AZA-001 trial, azacitidine nearly doubled the two-year overall survival rate compared to conventional care (51% vs. 26%).
If a treatment cycle is delayed due to scheduling issues or because blood counts have not recovered sufficiently, your haematologist will advise you on when to restart treatment. Delays of 1–2 weeks between cycles are common and usually do not significantly affect the overall treatment outcome. However, prolonged or frequent treatment interruptions may reduce the effectiveness of azacitidine. Always follow your doctor’s guidance regarding timing of treatment cycles and do not adjust the schedule on your own.
Yes, Azacitidine STADA Arzneimittel AG is a generic version that contains the same active substance (azacitidine), in the same strength (100 mg per vial, 25 mg/ml after reconstitution), and in the same pharmaceutical form (powder for suspension for injection) as the originator product. Generic medications must demonstrate bioequivalence to the reference product and meet the same stringent quality standards set by regulatory authorities such as the EMA. The efficacy and safety profile is considered equivalent to the originator.
Yes, azacitidine subcutaneous injections can often be administered in an outpatient or day-treatment setting, depending on your hospital’s practice and your clinical condition. Many patients attend the hospital or clinic daily for their 7 days of injections and then return home during the 21-day rest period. Some centres may also arrange for community nursing to administer the injections at home. However, during the first few treatment cycles, closer monitoring may be required, and hospitalisation may be necessary if complications such as severe infections or bleeding occur.
References
- European Medicines Agency (EMA). Azacitidine – Summary of Product Characteristics. Available at: www.ema.europa.eu. Accessed January 2026.
- Fenaux P, Mufti GJ, Hellström-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncology. 2009;10(3):223–232. doi:10.1016/S1470-2045(09)70003-8
- Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. Journal of Clinical Oncology. 2002;20(10):2429–2440. doi:10.1200/JCO.2002.04.117
- National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Myelodysplastic Syndromes. Version 1.2025. Available at: www.nccn.org.
- Platzbecker U, Kubasch AS, Homer-Bouthiette C, Prebet T. Current challenges and unmet medical needs in myelodysplastic syndromes. Leukemia. 2021;35(8):2182–2198. doi:10.1038/s41375-021-01265-7
- World Health Organization (WHO). Classification of Haematolymphoid Tumours, 5th Edition. Lyon: IARC Press; 2022.
- Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454–2465. doi:10.1182/blood-2012-03-420489
- Savona MR, Kolibaba K, Germán L, et al. An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. Blood. 2015;125(12):1857–1865.
- British National Formulary (BNF). Azacitidine. Available at: bnf.nice.org.uk. Accessed January 2026.
- Santini V, Prebet T, Fenaux P, et al. Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations. Leukemia Research. 2014;38(12):1381–1391. doi:10.1016/j.leukres.2014.09.008
Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, a multidisciplinary group of healthcare professionals with specialist expertise in haematology, oncology, and clinical pharmacology.
Medical Content Team
Specialist physicians in haematology and clinical pharmacology with documented academic background and clinical experience in myeloid malignancies
Medical Review Board
Independent panel reviewing all content according to international guidelines (EMA, FDA, NCCN, ESMO, WHO) and the GRADE evidence framework
Pharmacology Advisors
Clinical pharmacologists specialised in oncology drug therapy, drug interactions, and personalised dosing strategies
Patient Information Specialists
Experts in health literacy and patient communication, ensuring complex medical information is accessible and understandable to all audiences
All medical content follows the iMedic Editorial Standards and is regularly updated to reflect the latest evidence-based guidelines and clinical research. Our editorial process ensures independence from pharmaceutical industry influence.